| Literature DB >> 29525636 |
Maria C Sorbo1, Valeria Cento2, Velia C Di Maio1, Anita Y M Howe3, Federico Garcia4, Carlo F Perno5, Francesca Ceccherini-Silberstein6.
Abstract
Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available. The natural presence of resistance associated substitutions (RASs), as well as their rapid emergence during incomplete drug-pressure, are intrinsic characteristics of HCV that greatly affect treatment outcome and the chances to achieve a virolgical cure. To date, a high number of RASs in NS3, NS5A, and NS5B have been associated in vivo and/or in vitro with reduced susceptibility to DAAs, but no comprehensive RASs list is available. This review thus provides an updated, systematic overview of the role of RASs to currently approved DAAs or in phase II/III of clinical development against HCV-infection, discriminating their impact in different HCV-genotypes and DAAs, providing assistance for a fruitful use of HCV resistance testing in clinical practice.Entities:
Keywords: Direct acting antiviral agents; Fold-change; HCV genotypic resistance testing; HCV sequencing; Treatment failure
Mesh：
Substances：
Year: 2018 PMID： 29525636 DOI： 10.1016/j.drup.2018.01.004
Source DB: PubMed Journal: Drug Resist Updat ISSN： 1368-7646 Impact factor: 18.500